Order results by:
| Issue | Title | |
| Vol 12, No 4 (2019) | The health technology assessment system in Australia | Abstract similar documents |
| V. V. Omelyanovskiy, E. S. Saybel, T. P. Bezdenezhnykh, G. R. Khachatryan | ||
| "... influence the committee decision. In addition to the full reimbursement of pharmaceuticals, the committee ..." | ||
| Vol 12, No 2 (2019) | Health technology assessment and reimbursement of pharmaceuticals in Italy | Abstract similar documents |
| F. V. Gorkavenko, V. V. Omelyanovskiy, T. P. Bezdenezhnykh, G. R. Khachatryan | ||
| "... ) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-listing ..." | ||
| Vol 13, No 2 (2020) | Affordability of in vivo gene therapy. Problems and potential solutions | Abstract similar documents |
| V. V. Omelyanovskiy, N. Z. Musina, V. A. Lemeshko, A. A. Antonov, F. V. Gorkavenko | ||
| "... pharmaceutical market. The analysis of the methodology used in the found CESs was performed based on the given ..." | ||
| Vol 11, No 2 (2018) | Introduction of medical products into healthcare practice and costs reimbursement: European experience | Abstract similar documents |
| V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii | ||
| Vol 11, No 3 (2018) | What is the role of antineoplastic drug safety in reimbursement decision making? | Abstract similar documents |
| A. S. Kolbin, A. A. Kurylev | ||
| "... to reimbursement in Russia has grown from 15% to 28%. This group of drugs is characterized by severe adverse events ..." | ||
| Vol 14, No 1 (2021) | Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy | Abstract similar documents |
| V. A. Lemeshko, K. I. Matrenin, V. V. Omelyanovskiy, Yu. V. Vasilyeva, G. R. Khachatryan, L. A. Kolganov | ||
| "... of the procedure of the list formation (reimbursement of medicines by all the registered indications). The results ..." | ||
| Vol 9, No 1 (2016) | MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 | Abstract similar documents |
| A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum | ||
| "... inclusion and exclusion into the reimbursement lists in Russian Federation. The liner mathematical model ..." | ||
| Vol 7, No 4 (2014) | IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? | Abstract similar documents |
| V. V. Omelyanovskiy | ||
| "... reimbursement) shows a substantial variety and presence of national peculiarities; however the majority ..." | ||
| Vol 8, No 1 (2015) | PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| L. S. Melnikova | ||
| "... are used in foreign countries at reimbursement of costs for public drug supply. The author estimates ..." | ||
| Vol 12, No 2 (2019) | Organizational structure and funding of health technology assessment agencies around the world | Abstract similar documents |
| G. R. Khachatryan, V. V. Omelyanovskiy, L. S. Melnikova, S. S. Ratushnyak | ||
| "... : «organizational structure of HTA agency», «funding of HTA agency», «pharmaceutical», «reimbursement», «healthcare ..." | ||
| Vol 10, No 3 (2017) | Review of the current approaches to the assessment of the drug innovative potential worldwide | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva, V. V. Omel’yanovskii, G. R. Khachatryan, K. V. Gerasimova, V. A. Lemeshko, K. P. Konchits | ||
| "... significance of a new medical product and make an educated decision on the reimbursement, cost and priority ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... are registered in second-line, however only dasatinib is included in the government drug reimbursement program ..." | ||
| Vol 11, No 2 (2018) | Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations | Abstract similar documents |
| M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov | ||
| "... ) in 2018 provides for the reimbursement for hospital stay expenses by the compulsory medical insurance fund ..." | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... reimbursement. The present review demonstrates that just a few countries (englandandWales,Thailand,Poland,USA ..." | ||
| Vol 16, No 2 (2023) | Providing pharmaceutical consultation to visitors of pharmacy organizations in routine pharmaceutical practice | Abstract similar documents |
| M. S. Soboleva | ||
| "... to pharmacy organizations during provision of pharmaceutical assistance. Material and methods. A prospective ..." | ||
| Vol 5, No 1 (2012) | PHARMACOECONOMICS AS A NEW INSTRUMENT OF PHARMACEUTICAL MARKETING | Abstract similar documents |
| M. V. Protsenko, N. I. Koroleva | ||
| "... results as a new instrument in pharmaceutical marketing lets marketing specialists know what information ..." | ||
| Vol 6, No 3 (2013) | THE ANALYSIS OF THE MARKET OF PHARMACEUTICALS FOR DYSMENORRHEA TREATMENT | Abstract similar documents |
| N. Yu. Cherkasova, A. V. Fomina, O. V. Filippova | ||
| "... The range and sales analysis of pharmaceuticals for the dysmenorrhea treatment on the market ..." | ||
| Vol 11, No 3 (2018) | The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia | Abstract similar documents |
| V. V. Omelyanovsky, V. K. Fedyaeva, N. Z. Musina | ||
| "... the principles of health technologies assessment (HTA) and the reimbursement strategies in Russia have been put ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... , incremental cost-effectiveness ratio) is used as one of the decision-making criteria for reimbursement in some ..." | ||
| Vol 15, No 1 (2022) | The analysis of the consumption level of antihypertensive drugs and statins in a retail pharmacy of the Samara Region in 2015–2020 | Abstract similar documents |
| I. K. Petrukhina, P. A. Lebedev, E. P. Gladunova, T. K. Ryazanova, A. A. Garanin, P. R. Blinkova | ||
| "... drugs, their fixed combinations (FC), as well as statins in the retail sector of the pharmaceutical ..." | ||
| Vol 18, No 1 (2025) | Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia | Abstract similar documents |
| A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova | ||
| "... ) is altering the structure of the pharmaceutical market by amplifying the share of domestic manufacturers ..." | ||
| Vol 18, No 1 (2025) | Problems of using phenol (hydroxybenzene) and parabens as pharmaceutical stabilizers: analysis using machine learning methods | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova | ||
| "... toxicity tests) and are used in pharmaceutical, cosmetic and food industries as stabilizers/preservatives ..." | ||
| Vol 5, No 2 (2012) | WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM | Abstract similar documents |
| A. I. Borodin | ||
| "... Research of experience of the firm which is engaged in pharmaceutical business, has confirmed ..." | ||
| Vol 7, No 2 (2014) | THE ANALYSIS OF THE LIPETSK PHARMACEUTICAL MARKET OF NASAL GLUCOCORTICOSTEROID | Abstract similar documents |
| K. V. Danilova, I. M. Razdorskaya | ||
| "... in the present paper we have studied a group of pharmaceutical drugs used in the treatment ..." | ||
| Vol 17, No 1 (2024) | Compounding pharmacy regulations: experience of the Latvian pharmaceutical market | Abstract similar documents |
| D. D. Mamedov, D. S. Yurochkin, D. D. Zelikova, S. E. Erdni-Garyaev, Z. M. Golant, I. A. Narkevich | ||
| "... pharmaceutical market to improve approaches for statutory regulation of this special and socially significant ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract similar documents |
| D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
| "... method with a sensitivity analysis. Further, the calculations of the amounts of reimbursement of medical ..." | ||
| Vol 13, No 4 (2020) | Concept of value-based healthcare | Abstract similar documents |
| N. Z. Musina, V. V. Omelyanovskiy, R. V. Gostischev, O. A. Sukhorukikh, V. K. Fedyaeva, N. N. Sisigina, D. G. Shchurov | ||
| "... processes including procurement of drugs and medical devices, their pricing, and reimbursement. ..." | ||
| Vol 7, No 4 (2014) | ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva | ||
| "... are the representatives of the Ministry of Health, pharmaceutical companies, distributors and pharmacy organizations ..." | ||
| Vol 15, No 3 (2022) | Prospects for the use of chondroitin sulfate and glucosamine sulfate in the treatment of patients with obesity-associated osteoarthritis (metabolic syndrome) | Abstract similar documents |
| I. Yu. Torshin, О. A. Gromova, A. M. Lila | ||
| Vol 14, No 1 (2021) | Differences in the standardization of medicinal products based on extracts of chondroitin sulfate | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, B. Ts. Zaychik, E. V. Shikh, A. O. Ruzhitskiy, A. N. Galustyan, I. S. Sardaryan, I. V. Sarvilina | ||
| "... . It was shown that the assessments of the pharmaceutical quality of the studied extracts made by the elemental ..." | ||
| Vol 16, No 4 (2023) | Sales of antitumor drugs in the retail segment of the Russian pharmaceutical market | Abstract similar documents |
| I. K. Petrukhina, T. K. Ryazanova, E. P. Gladunova, A. M. Lazarev, A. A. Krivova | ||
| "... at the expense of personal funds of citizens in the retail sector of the pharmaceutical market of the Russian ..." | ||
| Vol 16, No 1 (2023) | Compounding pharmacy regulations: experience of the North American pharmaceutical market | Abstract similar documents |
| D. D. Mamedov, D. S. Yurochkin, A. A. Leshkevich, S. E. Erdni-Garyaev, Z. M. Golant, I. A. Narkevich | ||
| "... of the compounding pharmacy regulation in North American pharmaceutical market. The main imperatives are identified ..." | ||
| Vol 14, No 2 (2021) | Analysis of the availability and affordability of pharmaceuticals for children in need of palliative care | Abstract similar documents |
| D. M. Medvedeva, I. A. Narkevich, O. D. Nemyatykh | ||
| "... Objective: to analyze the availability and affordability of pharmaceuticals for children in need ..." | ||
| Vol 14, No 2 (2021) | Impact of disease information (Ebola and COVID-19) on the pharmaceutical sector in Russia and USA | Abstract similar documents |
| E. A. Fedorova, D. O. Afanasyev, A. V. Sokolov, M. P. Lazarev | ||
| "... and the dynamics of the return on shares of the pharmaceutical sector for Russia and the United States. Material ..." | ||
| Vol 14, No 2 (2021) | Survey-based evaluation of the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome | Abstract similar documents |
| M. A. Chernyavskaya, I. A. Narkevich | ||
| "... Objective: to evaluate the awareness of pharmaceutical specialists on the pharmacotherapy ..." | ||
| Vol 17, No 2 (2024) | Mathematical modeling and analysis of export trends for certain pharmaceutical groups | Abstract similar documents |
| А. R. Shaikhislamova, N. А. Gasratova | ||
| "... (pharmaceutical products) of the commodity nomenclature of foreign economic activity of the Eurasian Economic ..." | ||
| Vol 18, No 2 (2025) | Cosmetics as a product group of the Russian pharmaceutical market: analysis of competition and level of dominance | Abstract similar documents |
| N. I. Markov, L. S. Treshchetkina | ||
| "... ) cosmetics. Material and methods. The study was based on annual reports on the Russian pharmaceutical market ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... and a biosimilar registered on the pharmaceutical market, the calculation was based on the median of the registered ..." | ||
| Vol 5, No 1 (2012) | UN MILLENNIUM DEVELOPMENT GOALS INDICATORS ON PROBLEMS OF ACCESS TO ESSENTIAL MEDICINES AND ENHANCEMENT OF LOCAL PHARMACEUTICAL PRODUCER IN DEVELOPING COUNTRIES | Abstract similar documents |
| A. Y. Kulikov, A. G. Voskanyan | ||
| "... The article covers the key issues of local pharmaceutical production and ensuring of equitable ..." | ||
| Vol 10, No 4 (2017) | THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT SEGMENT | Abstract similar documents |
| D. V. Lukyantseva, L. S. Mel’nikova, A. P. Tatarinov | ||
| Vol 12, No 2 (2019) | Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available | Abstract similar documents |
| F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev | ||
| "... names (INN) of anticancer drugs, whose generics or biosimilars entered the Russian pharmaceutical market ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| Vol 13, No 2 (2020) | Biological effects of phytoestrogens: clinical effectiveness and potential application in the treatment of climacteric syndrome | Abstract similar documents |
| M. A. Chernyavskaya, I. A. Narkevich | ||
| Vol 15, No 1 (2022) | Application of chondroprotective agents to inhibit osteodestructive processes in the subchondral bone in patients with osteoarthritis | Abstract PDF (Eng) similar documents |
| О. А. Gromova, А. М. Lila, I. Yu. Torshin, I. А. Reier | ||
| Vol 17, No 4 (2024) | Scenario modeling of the drug prescription process for children: application of machine learning methods | Abstract similar documents |
| А. А. Kondrashov, М. М. Kurashov, Е. Е. Loskutova | ||
| "... systems of the pharmaceutical care structure. Material and methods. The study was based on data on drug ..." | ||
| Vol 18, No 2 (2025) | Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration | Abstract similar documents |
| F. V. Gorkavenko, A. B. Goryachev, O. V. Ashikhmina, D. V. Fedyaev, N. V. Ignateva, E. A. Smolyarchuk, A. V. Kirchenko, D. D. Tkachenko, V. I. Brazhnikova | ||
| "... Background. Studies on the pharmaceutical provision of neovascular age-related macular ..." | ||
| Vol 15, No 4 (2022) | Analysis of the main indicative values of the pharmaceutical market retail sectors in the constituent entities of the Russian Federation | Abstract similar documents |
| I. К. Petrukhina, Т. К. Ryazanova, А. I. Khusainova, А. V. Egorova, P. R. Blinkova | ||
| "... Objective: to study various typological characteristics of the retail pharmaceutical market sector ..." | ||
| Vol 14, No 2 (2021) | Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, A. G. Chuchalin, Yu. I. Zhuravlev | ||
| "... the pharmaceuticals registered in the Anatomical, Therapeutic, and Chemical Classifier (ATC). Material and methods ..." | ||
| Vol 18, No 1 (2025) | The sale of medicines used for diabetes mellitus treatment in retail segment of Russian pharmaceutical market | Abstract similar documents |
| I. K. Petrukhina, A. M. Lazarev, T. K. Ryazanova, P. A. Lebedev, E. P. Gladunova, G. T. Glembotskaya | ||
| "... for the treatment of diabetes mellitus (DM), sold in the retail sector of the pharmaceutical market of the Russian ..." | ||
| Online First | Implementation of modern quality management system requirements in the production management of reference standards for pharmaceuticals and medicine | Abstract similar documents |
| V. I. Gegechkori, A. M. Sukhanova, N. O. Belyavskiy, G. V. Ramenskaya | ||
| "... ) in the production of reference materials (RMs) for pharmaceutical and medical applications, as well as to assess ..." | ||
| 1 - 50 of 82 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
